From the INTERNATIONAL SEARCHING AUTHORITY

To: JOY ANN G. SERAUSKAS

PCT

227 WEST MONROE STREET CHICAGO, IL 60606		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY				
		(PCT Rule 43bis.1)				
·		Date of mailing (day/month/year)	17 JUN 2308			
Applicant's or agent's file reference		FOR FURTHER ACTION See paragraph 2 below				
038586-0338001						
International application No. International filing date			Priority date (day/month/year)			
PCT/US07/26315 26 December 2007 (26.1)			22 December 2006 (22.12.2006)			
International Patent Classification (IPC) or both national classification and IPC						
IPC: G01N 33/53(2006.01),33/567(2006.01);A01N 37/18(2006.01);A61K 38/00(2006.01) USPC: 435/7.1,7.2;514/2						
Applicant						
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA						
1. This opinion contains indications relating to the following items:						
Box No. I Basis of the opinion	Box No. I Basis of the opinion					
Box No. II Priority	Priority					
Box No. III Non-establishmen	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Box No. IV Lack of unity of in	nvention					
Box No. V Reasoned stateme applicability; citat	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
Box No. VI Certain document	Certain documents cited					
Box No. VII Certain defects in	Certain defects in the international application					
Box No. VIII Certain observation	Certain observations on the international application					
2. FURTHER ACTION						
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.						
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.						
For further options, see Form PCT/ISA/220.						
3. For further details, see notes to Form PCT/						
Name and mailing address of the ISA/US	Date of complete	tion of this opinion	Authorized officer			
Mail Stop PCT, Attn: ISA/US Commissioner for Patents	21 May 2008 (2	21.05.2008)	/Rebert Landsman/			
P.O. Box 1450 Alexandria, Virginia 22313-1450			Telephone No. 571-272-1600			
Facsimile No. (571) 273-3201						

Form PCT/ISA/237 (cover sheet) (April 2007)



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US07/26315

Box No	o. I Basis of this opinion					
1. With regard to the language, this opinion has been established on the basis of:						
\boxtimes	the international application in the language in which it was filed					
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).					
2.	2. This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to this					
2 Wish	Authority under Rule 91 (Rule 43bis.1(a)) regard to any nucleotide and/or amino acid sequence disclosed in the international application, this opinion has been					
	ished on the basis of:					
a.	type of material					
	a sequence listing					
	table(s) related to the sequence listing					
b.	format of material					
	on paper					
	in electronic form					
^	time of filing/furnishing					
C.	c. time of filing/furnishing contained in the international application as filed.					
	filed together with the international application in electronic form.					
	· · · · · · · · · · · · · · · · · · ·					
	furnished subsequently to this Authority for the purposes of search.					
4. 🛛	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
5. Additi	onal comments:					
•						
•						
	7/(SA/237(Box No. 1) (April 2007)					



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US07/26315

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement YES Claims Please See Continuation Sheet Novelty (N) NO Claims Please See Continuation Sheet YES Claims Please See Continuation Sheet Inventive step (IS) NO Claims Please See Continuation Sheet YES Industrial applicability (IA) Claims Please See Continuation Sheet Claims Please See Continuation Sheet NO

2. Citations and explanations:

Claims 1-5, 7-13, 15-19, 21-25, 27-31, 39, 40 and 42 lack novelty under PCT Article 33(2) as being anticipated by Murray et al. (WO2005072403). The claims recite various methods of increasing the rate of bone formation and fusion by administering a protein comprising SEQ ID NO:11, or a fragment thereof, which would include SEQ ID NO:1. The claims also recite the isolated polypeptides themselves. Murray teach a protein 100% identical to SEQ ID NO:1 (see attached Sequence Comparison). Murray also teaches that this protein can be used with other bone growth factors, including human BMP-2 to induce calcification and osteogenesis (pages 1-6 and Example 2, especially paragraphs [0028], [0029]) and TGF-b ([0032]).

Claims 1-5, 7-13, 15-19, 21-25, 27-31, 39, 40 and 42 lack an inventive step under PCT Article 33(3) as being obvious over Murray (WO2005072403) since the claims lack novelty as discussed above.

Claims 6, 14, 20, 26, 32-38 and 41 meet the criteria set out in PCT Article 33(2)-33(3), because the prior art does not teach, or fairly suggest the claimed polypeptide or nucleic acids.

Claims 1-42 meet the criteria set out in PCT Article 33(4), and thus possess industrial applicability because the subject matter claimed can be made or used in industry.



International application No. PCT/US07/26315

Supplemental Box In case the space in any of the p	receding boxes is not sufficient.		
		•	
·			
			·
	•		
		-	
	•		
V.1. Reasoned Statements:	ositive (Yes) with respect to claims 6, 14, 20, 20	6 32 35.38 <i>4</i> 1	
The opinion as to Novelty was no The opinion as to Inventive Step	egative (No) with respect to claims 1-5, 7-13, I was positive (Yes) with respect to claims 6, 14	15-19, 21-25, 27-31, 33, 34, 1, 20, 26, 32, 35-38, 41	
The opinion as to Inventive Step The opinion as to Industrial App	was negative(NO) with respect to claims 1-5, licability was positive (YES) with respect to cl	7-13, 15-19, 21-25, 27-31, 3 laims 1-42	33, 34, 39, 40 and 42
The opinion as to Industrial App	licability was negative(NO) with respect to cla	ims NONE	
	•		
	•		
		·	
	•		•
	·		•